<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Design of experiments Clinical research Pharmaceutical industry Pharmacology Clinical trial Interim analysis Clinical study design Drug development FDA Special Protocol Assessment Medical statistics Science Research |
Add to Reading List |
Microsoft Word - 9124dft.doc | Microsoft Word - Savient press release Puricase SPAdocDocID: 1qW9f - View Document |
| Microsoft Word - Savient Announces FDA Advisory PaneldocDocID: 1q0EW - View Document |
| Microsoft Word - 9124dft.docDocID: 1ak2h - View Document |
| ACUSPHERE INC. REACHES SPECIAL PROTOCOL ASSESSMENT AGREEMENT WITH FDA FOR IMAGIFY™ PHASE 3 PLACEBO-CONTROLLED TRIAL LEXINGTON, MASS., June 8, [removed]Acusphere, Inc. (ACUS.PK), a specialty pharmaceutical company, todayDocID: YRPF - View Document |
| Microsoft Word - StarpharmadocxDocID: Wa8v - View Document |